-

12:54:03 PM

ZIMV Stock News

ZIMV - ZimVie Inc

09/26/23 8:00 AM

Nasdaq : ZIMV

fda approval

ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced

RHEA-AI

neutral

08/17/23 8:00 AM

Nasdaq : ZIMV

ZimVie Expands Development Cooperation Agreement with Brainlab AG to Include Co-Marketing

ZimVie Inc. (Nasdaq: ZIMV), a global life

RHEA-AI

positive

08/10/23 8:00 AM

Nasdaq : ZIMV

fda approval

ZimVie Announces FDA Approval for New Mobi-C® Implant

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that on August 1 st, 2023, the U.S. Food and Drug

RHEA-AI

neutral

08/02/23 4:05 PM

Nasdaq : ZIMV

earnings

ZimVie Reports Second Quarter 2023 Financial Results and Provides Update to Annual Guidance

Third Party Net Sales of $224.9 million Net Loss of ($23.4) million; Net Loss Margin of (10.4%); Adjusted Net Income [1] of $4.3 million Diluted EPS of ($0.89); Adjusted Diluted EPS [1] of $0.17 Adjusted EBITDA [1] of $29.7 million; Adjusted EBITDA margin [1] of 13.2% WESTMINSTER, Colo., Aug. 02,

RHEA-AI

negative

07/12/23 4:05 PM

Nasdaq : ZIMV

conferencesearnings

ZimVie to Report Second Quarter 2023 Financial Results on August 2, 2023

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. Company management will host a

RHEA-AI

neutral

05/22/23 4:05 PM

Nasdaq : ZIMV

conferences

ZimVie to Present at the Stifel 2023 Jaws & Paws Conference

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that the company will be participating in the upcoming Stifel 2023 Jaws & Paws Conference in New York. Management will be hosting a

RHEA-AI

neutral

05/03/23 4:05 PM

Nasdaq : ZIMV

earnings

ZimVie Reports First Quarter 2023 Financial Results and Provides Update to Annual Guidance

Third Party Net Sales of $225.1 million Net Loss of ($30.0) million; Net Loss Margin of (13.3%); Adjusted Net Income [ 1] of $6.7 million Diluted EPS of ($1.14); Adjusted Diluted EPS [ 1] of $0.25 Adjusted EBITDA [ 1] of $32.1 million; Adjusted EBITDA margin [1] of 14.3% Prepaid required principal

RHEA-AI

negative

04/27/23 8:30 AM

Nasdaq : ZIMV

ZimVie Opens State-of-the-Art Dental Science Educational and Training Institute in Palm Beach Gardens, Florida

ZimVie Inc. (Nasdaq: ZIMV), a global

RHEA-AI

neutral

04/13/23 8:30 AM

Nasdaq : ZIMV

ZimVie Announces the Recent Launches of RegenerOss® CC Allograft Particulate and RegenerOss® Bone Graft Plug

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine

RHEA-AI

neutral

04/12/23 4:10 PM

Nasdaq : ZIMV

conferencesearnings

ZimVie to Report First Quarter 2023 Financial Results on May 3, 2023

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. Company management will host a

RHEA-AI

neutral